Our IVDResearch

About IVD

At the beginning of the establishment in 2006, SCI had previously consisted of two divisions: Stem Cell and Cancer Research. Both divisions had produce qualified research publications as well as generating commercializable products. Over time, as a response to the pandemic situation, in 2020, SCI expanded its area of research to include infectious diseases and developed saliva-based COVID-19 RT-PCR kit. In 2021, henceforward, Cancer Research Division changed its name to In Vitro Diagnostic (IVD) Division to address unmet medical needs and facilitate the new drug development.


Contains a compilation of IVD research publications


Contains a compilation of IVD galleries

Our Stem CellResearch

About Stem Cell

Since 2006 Stem Cell and Cancer Institute (SCI) has been doing many kinds of research in stem cell therapy and other cell therapy in collaboration with several educational hospitals and public universities to provide stem cell and cell therapy for degenerative disease and injury, such as osteoarthritis, non-union bone fracture, spinal cord injury, stroke, Parkinson, myocardial infarction, cardiomyopathy, and critical limb ischemia. In 2013, SCI built up Regenerative and Cellular Therapy (ReGeniC) under PT Bifarma Adiluhung which provides cell manufacturing facilities to support the needs of stem cell and cell therapy development and research. Since then, SCI has been doing much research in cellular therapy and active in research publications


Contains a compilation of Stem Cell research publications


Contains a compilation of Stem Cell galleries

Quick Contact

If you have any questions, simply use the following contact details.


Jl. Jenderal Ahmad Yani Jl. Pulo Mas No.2, RT.3/RW.13, Kayu Putih, Kec. Pulo Gadung, East Jakarta City, Special Capital Region of Jakarta 13210




(021) 47860173




If you have are dedicated, conscientious, and willing to give the best of you, be the part of our team.